Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies

 
• By Alaric DeArment

Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.
• Source: Shutterstock

Adaptimmune Therapeutics plc has a powerful new partner in Roche Holding AG’s Genentech for its allogeneic T-cell therapy program, based on Adaptimmune’s induced pluripotent stem cell (iPSC)-derived platform. The deal gives the biotech a leg up in a race that has lately attracted a number of large biopharma industry players, but also marks a significant vote of confidence in Adaptimmune’s programs and for cell therapies in solid tumors overall.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business